인간성장호르몬 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측(2018-2028년) : 용도별, 유통 채널별, 지역별, 경쟁

In 2022, the Global Human Growth Hormone Market reached a valuation of USD 4.03 billion, and it is expected to experience substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 12.35% through 2028. The global Human Growth Hormone (HGH) market has undergone significant growth and transformation recently, driven by various factors. These factors include an aging population, increased awareness of HGH-related conditions, advancements in biotechnology, and changing consumer preferences for anti-aging and wellness solutions.

Human Growth Hormone, also known as somatotropin, is a vital hormone produced by the pituitary gland, a small structure located at the base of the brain. While it plays a crucial role in the growth and development of the human body, its functions extend beyond height regulation. HGH is primarily responsible for promoting growth during childhood and adolescence by stimulating bone and cartilage growth to help children achieve their full genetic height potential. However, its roles continue into adulthood, where it regulates body composition, metabolism, and the repair and regeneration of cells.

The HGH market has witnessed substantial growth, surpassing expectations with a CAGR exceeding the projected rate. This growth is driven by a rising incidence of growth hormone deficiency (GHD) in both children and adults, as well as an increasing demand for anti-aging therapies. Additionally, the expanding global population, especially the aging segment, contributes to the market's expansion. There is a growing awareness of the significance of HGH in managing growth disorders and its potential in anti-aging treatments, which has boosted demand in the market. Patients and healthcare professionals are increasingly recognizing the advantages of HGH therapy. Moreover, advances in biotechnology have led to improved methods of HGH production, making the hormone more accessible and cost-effective. This has broadened its applications in various medical contexts.

Key Market Drivers

Increasing Prevalence of Growth Hormone Deficiency (GHD)

One of the primary drivers of the HGH market is the rising incidence of Growth Hormone Deficiency (GHD) in both children and adults. GHD can result from various causes, including genetic factors, trauma, or damage to the pituitary gland, and it can manifest as short stature in children or a range of health issues in adults. As awareness of GHD increases among healthcare professionals and the general public, more individuals are being diagnosed with this condition. Consequently, there is a growing demand for HGH therapy to address GHD-related health concerns. This trend is expected to continue driving market growth as early diagnosis and intervention become more common.

One significant factor contributing to the increased prevalence of GHD is improved diagnostic techniques. Advances in medical technology and our understanding of the endocrine system have made it easier to identify individuals with GHD. These diagnostic tools allow healthcare providers to detect the condition at an earlier stage, providing an opportunity for timely intervention and treatment. Moreover, the awareness of GHD's potential consequences has spurred efforts to diagnose the condition in a broader range of patients. It is not limited to individuals with extremely short stature but also encompasses those with milder forms of the deficiency. This expanded diagnostic approach has further boosted the number of people seeking HGH therapy. In the case of children with GHD, early intervention through HGH therapy can help them achieve normal growth and development, ultimately improving their quality of life. For adults with GHD, HGH therapy can alleviate various health issues associated with the condition, such as muscle weakness and increased fat mass. As a result, more healthcare professionals are prescribing HGH therapy to address the specific needs of their patients.

Advancements in Biotechnology

Advancements in biotechnology have revolutionized the production and accessibility of HGH. In the past, HGH was sourced from cadavers, which posed significant safety risks. Today, biotechnology allows for the creation of synthetic HGH through recombinant DNA technology. This has not only eliminated safety concerns but has also made HGH more affordable and readily available. The availability of recombinant HGH has expanded its use beyond medical applications, extending into cosmetic and wellness sectors. This has significantly boosted market growth, as a wider range of individuals seek HGH-based treatments for various purposes.

One of the significant impacts of biotechnological advancements is the improved safety profile of synthetic HGH. Previously, HGH derived from cadavers carried the risk of transmitting diseases, including Creutzfeldt-Jakob disease. With recombinant HGH, these safety concerns have been virtually eradicated, instilling greater confidence in both healthcare professionals and patients. Moreover, the increased availability and affordability of synthetic HGH have broadened its use beyond traditional medical applications. This expansion of potential applications has boosted the HGH market's growth. It has led to innovative therapies for a wide range of conditions, including growth hormone deficiencies, Turner syndrome, Prader-Willi syndrome, and chronic kidney disease. The versatility of synthetic HGH has also extended into the realm of wellness and cosmetics. Many individuals are turning to HGH-based treatments for their potential anti-aging benefits. As people age, their natural production of HGH decreases, leading to changes in body composition, including reduced muscle mass and increased fat accumulation. Synthetic HGH is now used by a growing number of individuals seeking to improve muscle tone, reduce body fat, and enhance overall vitality.

Rising Demand of Anti-Aging Therapies

HGH has gained significant popularity in the realm of anti-aging therapies. As people age, their natural production of HGH decreases, leading to changes in body composition, including reduced muscle mass, increased fat accumulation, and changes in skin quality. These age-related changes have fueled interest in HGH as a potential solution to mitigate the effects of aging. Many individuals turn to HGH therapy to improve muscle tone, skin elasticity, and overall vitality. While the efficacy of HGH in anti-aging remains a subject of debate and ongoing research, the pursuit of youthful appearances and enhanced well-being continues to drive market demand.

One of the key attractions of HGH therapy in the realm of anti-aging is its potential to improve muscle tone and reduce body fat. HGH stimulates the growth and repair of muscle tissue, making it a valuable asset for those seeking to maintain or regain muscle strength and definition as they age. Additionally, HGH can promote the breakdown of stored fat, helping individuals achieve a more favorable body composition. Another area of interest is the impact of HGH on skin quality. HGH has been linked to the production of collagen, a protein that provides elasticity and firmness to the skin. As individuals age, the decline in collagen production contributes to the development of wrinkles and sagging skin. HGH therapy is believed by some to improve skin quality, potentially reducing the visible signs of aging. The pursuit of anti-aging therapies has garnered significant attention in the wellness and cosmetic industries. A wide range of products and treatments claiming to possess anti-aging properties have flooded the market. HGH therapy, often administered through injections, has emerged as a sought-after option for those who are looking for more effective and lasting results.

Expanding Aging Population

The global population is undergoing a significant demographic shift, with a growing proportion of elderly individuals. This aging demographic presents a unique set of health challenges, including age-related conditions such as osteoporosis, muscle wasting, and cognitive decline.HGH therapy is increasingly considered as a potential intervention to address these age-related health issues. As the elderly population continues to expand, so does the market for HGH-based treatments designed to enhance their quality of life. The aging demographic is characterized by a higher proportion of elderly individuals, typically defined as those aged 65 and older. This demographic shift is primarily a result of increased life expectancy and declining birth rates. As people live longer, they inevitably encounter age-related health issues, including muscle loss, decreased bone density, cognitive decline, and increased vulnerability to chronic diseases.

One of the prominent age-related health concerns is the loss of muscle mass and strength, known as sarcopenia. This condition not only affects an individual's physical independence but also leads to an increased risk of falls and fractures. HGH plays a crucial role in promoting muscle growth and repair, making it a potential therapeutic option for addressing sarcopenia in older adults. Similarly, the aging process often leads to decreased bone density, which can result in osteoporosis and an increased susceptibility to fractures. HGH therapy has been explored as a means of improving bone health and reducing the risk of fractures in the elderly population. This application of HGH highlights its potential to enhance the quality of life for older individuals. Cognitive decline is another significant concern associated with aging. Some studies suggest that HGH may have a positive impact on cognitive function and memory, although the extent of its effectiveness in this regard is still a subject of research. Nevertheless, the potential cognitive benefits of HGH have piqued the interest of older adults seeking ways to maintain mental acuity as they age.

Key Market Challenges

Regulatory Scrutiny

One of the foremost challenges facing the HGH market is the strict regulatory scrutiny and legal restrictions surrounding its use. HGH has garnered attention for its potential misuse in sports and bodybuilding as a performance-enhancing substance. Many sports organizations, including the International Olympic Committee, World Anti-Doping Agency, and various professional sports leagues, have banned the use of HGH without a legitimate medical prescription. The regulatory landscape regarding HGH varies from country to country, with some nations imposing stringent controls and limitations. These regulations aim to prevent its unauthorized use for non-medical purposes, ensuring a level playing field in competitive sports. However, navigating these regulations can be challenging for individuals and healthcare professionals alike, often requiring detailed documentation and justification for legitimate medical use..

Safety Concerns

Another significant challenge in the HGH market relates to safety concerns associated with its misuse or improper administration. While HGH therapy can offer substantial benefits when used responsibly and under medical supervision, it is not without risks. Overuse or excessive dosages can lead to adverse side effects, including joint pain, carpal tunnel syndrome, edema, hypertension, and an increased risk of developing diabetes.

Additionally, the long-term effects of HGH therapy, especially in adults, are still not well understood, and research is ongoing. Patients must be closely monitored during HGH therapy to minimize potential risks. Safety concerns underscore the importance of responsible and qualified medical supervision in the administration of HGH.

Accessibility Issues

Access to HGH therapy can also be challenging for some individuals due to factors such as cost, insurance coverage, and geographic location. HGH therapy can be expensive, and insurance coverage may not always extend to its use for non-GHD conditions. This financial barrier can limit access to those who could potentially benefit from HGH for legitimate medical reasons. Furthermore, the availability of HGH therapy may vary depending on geographic location and healthcare infrastructure. In some regions, access to specialized healthcare providers and medical facilities equipped to administer HGH therapy may be limited, making it challenging for patients to receive the treatment they need.

Key Market Trends

Expanding Applications in Medicine

The medical applications of HGH have expanded beyond treating growth-related disorders. Today, HGH is used to treat a wide array of medical conditions, including chronic kidney disease, Turner syndrome, and Prader-Willi syndrome. Moreover, its off-label use has gained traction in addressing conditions like muscle wasting, hormonal imbalances, and even anti-aging treatments. As medical research continues to uncover new therapeutic applications for HGH, the market is poised for further growth. One notable application is in the management of chronic kidney disease (CKD). Individuals with CKD often experience muscle wasting and a decline in overall physical health. HGH therapy has shown promise in mitigating these symptoms, improving muscle mass, and enhancing overall quality of life for CKD patients. Additionally, HGH has found its way into the treatment regimen for Turner syndrome and Prader-Willi syndrome, both of which involve growth and developmental challenges. HGH can help children with these conditions achieve a more typical growth trajectory and improve their overall health outcomes.

Moreover, HGH has garnered attention in the management of conditions associated with aging. As people grow older, their natural production of growth hormone diminishes, leading to muscle loss, decreased bone density, and increased fat accumulation. Anti-aging and wellness clinics are increasingly offering HGH therapies to address these age-related issues, appealing to a demographic keen on maintaining youthful vitality and appearance.

Technological Advancements in HGH Delivery

Technological advancements in Human Growth Hormone (HGH) delivery methods have played a pivotal role in boosting the HGH market. HGH, a critical hormone responsible for growth and development, has traditionally been administered through painful and inconvenient injections. However, recent innovations have revolutionized the way HGH is delivered, making it more accessible and patient friendly. One of the most significant breakthroughs in HGH delivery is the development of HGH-releasing peptides. These peptides stimulate the body's natural production of growth hormone, eliminating the need for synthetic HGH injections. Peptides like GHRP-2 and GHRP-6 have gained popularity for their ability to boost HGH levels safely and effectively. This advancement has not only improved patient comfort but has also reduced the risk of side effects associated with synthetic HGH.

Another game-changing innovation in HGH delivery is the availability of oral HGH supplements. These supplements are designed to be taken in pill or capsule form, providing a convenient alternative to injections. While oral HGH supplements may not be as potent as injectable HGH, they are preferred by individuals who wish to avoid needles and injections. The market for oral HGH supplements has seen substantial growth due to their ease of use and broader consumer appeal.

Growing Research and Development Activities

The pharmaceutical industry is heavily invested in research and development related to HGH. Companies are actively working on developing innovative formulations and therapies that can provide the benefits of HGH without the associated risks and side effects. This ongoing research is likely to lead to breakthroughs in HGH-based treatments and drive market growth by offering safer and more effective options to consumers.

Segmental Insights

Application Insights

Based on the application, the Turner syndromes segment emerged as the dominant player in the global market for Human Growth Hormone in 2022.This is attributed to the increasing recognition of Human Growth Hormone (HGH) as a valuable therapeutic option for individuals with Turner syndrome. HGH therapy has demonstrated significant clinical efficacy in improving the growth and development of individuals with Turner syndrome. It can help increase height, improve bone density, and mitigate some of the associated health issues. As a result, healthcare providers increasingly prescribe HGH for individuals with Turner syndrome, contributing to the segment's dominance.

There has been a growing awareness among both patients and healthcare professionals about the benefits of HGH therapy for Turner syndrome. As more individuals with the condition and their families become informed about treatment options, the demand for HGH in this segment has risen. HGH therapy not only addresses physical growth but also contributes to an improved quality of life for individuals with Turner syndrome. This comprehensive approach to healthcare has gained favor among both patients and healthcare providers, driving the segment's prominence.

Distribution Channel Insights

Based on the distribution channel, the hospital pharmacy segment emerged as the dominant player in the global market for Human Growth Hormone in 2022. This is attributed to several key factors including medical supervision and expertise, patient monitoring, access to specialized services, etc. Hospitals provide a controlled and medically supervised environment, ensuring that HGH therapy is administered under the guidance of healthcare professionals with expertise in endocrinology and related fields. This medical oversight instills confidence in patients and healthcare providers regarding the safety and efficacy of HGH treatment.

Hospital pharmacies offer comprehensive patient monitoring, which is crucial when administering HGH therapy. Regular check-ups and evaluations allow healthcare providers to adjust the treatment plan as needed, optimizing outcomes and minimizing potential side effects. This level of care is especially important for conditions requiring long-term HGH therapy. Hospitals typically employ multi-disciplinary care teams, including endocrinologists, pediatricians, nurses, and pharmacists, who collaborate to provide holistic care to patients receiving HGH therapy.

Regional Insights

North America emerged as the dominant player in the global Human Growth Hormone market in 2022, holding the largest market share. This is on account of several key factors such as advanced healthcare infrastructure, high prevalence of HGH-related conditions, and rising awareness and diagnosis.

North America boasts one of the most advanced healthcare infrastructures globally, with state-of-the-art hospitals, medical facilities, and research institutions. This robust healthcare ecosystem facilitates the diagnosis and treatment of conditions that require HGH therapy, contributing to the region's prominence in the market. North America has a significant prevalence of conditions that necessitate HGH therapy. This includes growth hormone deficiencies in children, Turner syndrome, and Prader-Willi syndrome, among others. The substantial patient population with these conditions creates a strong demand for HGH in the region.

Key Market Players

• AnkeBio Co. Ltd

• EMD Serono Inc.

• F.Hoffmann-La Roche Ltd

• Ferring BV

• Ipsen SA

• Eli Lilly and Company

• Novo Nordisk AS

• Pfizer Inc.

• Teva Pharmaceutical Industries Ltd

• Sandoz International GmbH (Novartis AG)

Report Scope:

In this report, the Global Human Growth Hormone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Growth Hormone Market, By Application:

• Growth Hormone Deficiency
• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Other Applications

Human Growth Hormone Market, By Distribution Channel:

• Hospitals and Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels

Human Growth Hormone Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Human Growth Hormone Market.

Available Customizations:

• Global Human Growth Hormone market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Growth Hormone Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Other Applications)
  • 5.2.2. By Distribution Channel (Hospitals and Retail Pharmacies, Online Pharmacies, Other Distribution Channels)
  • 5.2.3. By Company (2022)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Human Growth Hormone Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Growth Hormone Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Mexico Human Growth Hormone Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Canada Human Growth Hormone Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application
      • 6.3.3.2.2. By Distribution Channel

7. Europe Human Growth Hormone Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Human Growth Hormone Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Germany Human Growth Hormone Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Human Growth Hormone Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Human Growth Hormone Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Human Growth Hormone Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application
      • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Human Growth Hormone Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human Growth Hormone Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Human Growth Hormone Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. South Korea Human Growth Hormone Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. Japan Human Growth Hormone Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Human Growth Hormone Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application
      • 8.3.5.2.2. By Distribution Channel

9. South America Human Growth Hormone Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human Growth Hormone Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Human Growth Hormone Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Human Growth Hormone Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Human Growth Hormone Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Human Growth Hormone Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Human Growth Hormone Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Human Growth Hormone Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Application

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Products & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. AnkeBio Co. Ltd
  • 15.6.2. EMD Serono Inc.
  • 15.6.3. F.Hoffmann-La Roche Ltd
  • 15.6.4. Ferring BV
  • 15.6.5. Ipsen SA
  • 15.6.6. Eli Lilly and Company
  • 15.6.7. Novo Nordisk AS
  • 15.6.8. Pfizer Inc.
  • 15.6.9. Teva Pharmaceutical Industries Ltd
  • 15.6.10. Sandoz International GmbH (Novartis AG)

16. Strategic Recommendations